Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Phase 2 Completed 41 enrolled Ardea Biosciences, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects of RDEA3170 administered in combination with allopurinol compared with allopurinol administered alone in adult subjects with gout.

Timeline

Start: 2015-07-28
Primary completion: 2015-11-19
Completion: 2016-06-02

Publications

Fleischmann R, Winkle P, Miner JN, Yan X, Hicks L, Valdez S, Hall J, Liu S, Shen Z, Gillen M, Hernandez-Illas M. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open. 2018 Feb 8;4(1):e000584. doi: 10.1136/rmdopen-2017-000584. eCollection 2018.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Allopurinol	Small molecule	300 mg	—
Subject	Allopurinol	Small molecule	600 mg	—
Subject	Verinurad	Small molecule	2.5 mg	Oral
Subject	Verinurad	Small molecule	5 mg	Oral
Subject	Verinurad	Small molecule	7.5 mg	Oral
Subject	Verinurad	Small molecule	10 mg	Oral
Subject	Verinurad	Small molecule	15 mg	Oral
Subject	Verinurad	Small molecule	20 mg	Oral

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Summary

Timeline

Publications

Drugs

Indications